31 results about "Urothelium" patented technology

The invention belongs to the field of biological fluid detection in vitro, and concretely relates to a urine exfoliated tumor cell micro-fluidic chip detection technology aiming at urothelium carcinoma. The micro-fluidic chip comprises a sample inlet, a cell capturing area and a sample outlet which are connected sequentially, wherein the cell capturing area is provided with a plurality of cell sorting devices; each cell sorting device is formed by three columnar bulges arranged in an arc shape; a gap exists between every two columnar bulges; an arc-shaped opening is used as a liquid flow inlet; gaps at two sides of each middle columnar bulge are used as liquid flow outlets which are symmetrically distributed. According to the urine exfoliated tumor cell micro-fluidic chip detection technology provided by the invention, various cells in urine are separated and captured, multiple downstream cytology staining methods can be compatible for realizing cell recognition, the detection accuracy of urine exfoliated tumor cells in human urine is improved, the dependency on subjective experiences of pathology doctors in a conventional method is avoided, and the whole process is noninvasive. In addition, a lossless cell capturing and recovering manner lays a foundation on downstream molecular biology analysis.

The invention discloses a porous bladder acellular matrix retaining bioactive factors and a preparation method thereof. A bladder of a pig, a rabbit, a dog or cattle is handled by digestive juice, hypotonic buffer solution, hypertonic buffer solution with surfactants, buffer solution with nuclease, and deionized water. An abacterial bladder acellular matrix is obtained by cooling, freezing out and sterilizing. The bladder acellular matrix is not provided with cells, an urinary tract epithelial layer, a submucous layer or a blood circulatory system, thus having good biocompatibility and appropriate ultrastructural structure. Bioactive factors are retained, including cell adhesive factors, growth factors and chemokines. Therefore, the bladder acellular matrix is an ideal scaffold material for a bladder in tissue engineering.

Methods for the treatment of patients with HER2-positive, HER2-amplified and / or HER2-mutated advanced cancer by administration of pertuzumab plus trastuzumab are disclosed. In one aspect, the cancer is advanced HER2-positive, HER2-amplified and / or HER2-mutated colorectal, biliary, bladder, urothelial, salivary, lung, pancreatic, ovarian, prostate, or skin cancer. In another aspect, the cancer is HER2-positive, HER2-amplified and / or HER2-mutated colorectal, biliary, bladder, urothelial, salivary, lung, pancreatic, ovarian, prostate, or skin cancer that is refractory to one or more other treatment regimens.

The invention discloses an application of YTHDF2 in diagnosis, prevention and treatment of urothelium carcinoma. The invention discloses the application of a reagent for detecting YTHDF2 gene in preparing products for diagnosing urothelium carcinoma and also discloses the application of an inhibitor of YTHDF2 gene expression in preparing drugs for treating or preventing urothelium carcinoma. The invention firstly confirms the function of YTHDF2 in urothelium carcinoma; expression quantity of YTHDF2 in urothelium carcinoma tissues is up-regulated and multiplication and migration of urothelium carcinoma cells are promoted; YTHDF2 can be used as a potential target for diagnosing and treating clinic urothelium carcinoma.

The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety. The present invention provides pharmaceutical compositions for the treatment of cancer comprising an antibody that binds to 67LR in an amount effective to reduce cancer stem cells and / or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.

Provided herein are urine progenitor cells and methods for producing a culture of urine progenitor cells from a urine sample. The cells may be selected based upon the use of a selective cell medium, based upon morphology, and / or by selecting cell-specific markers. Also provided is an isolated urine progenitor cell that is c-kit positive and can differentiate into urothelium, smooth muscle, endothelium or interstitial cells. Methods of use of urine progenitor cells are provided, wherein cell are seeded onto a tissue scaffold are provided. Methods of treating a subject in need thereof are also provided, including providing a bladder tissue substrate that includes differentiated UPCs and transplanting the substrate into the patient. Finally, kits are provided that include a container suitable for the transport of a urine sample; media; one or more antibiotics; a package for holding said container, media, and antibiotics; and optionally, instructions for use.

The invention relates to a production of a recombinant human keratinocyte growth factor-1 (KGF-1) and discloses a recombinant plasmid of the gene of the recombinant human keratinocyte growth factor-1,a method of expression of keratinocyte growth factors after the recombinant plasmid is electro-transfected into Chinese hamster ovary (CHO), and purification processes of the recombinant plasmid. Therecombinant human keratinocyte growth factor-1 can significantly promote proliferation of 4MBr-5 cells and accordingly is applicable to treating skin and mucosal tissue damage-related diseases, lungdamage-related diseases and bladder and urothelium damage-related diseases.

The invention provides a new human urothelial carcinoma tumor marker-human tumor necrosis factor receptor superfamily TNFRSF25 and a hybridoma cell generating a monoclonal antibody resisting the tumor marker and a monoclonal antibody DTUC1 secreted thereby, wherein the monoclonal antibody DTUC1 is secreted by the hybridoma with collection number CGMCC No.8118. The monoclonal antibody DTUC1 is in positive reaction with the human urothelial carcinoma tissue and urothelial carcinoma cell lines such as 5637, UMUC3, SW780, J82, T24 and RT4, and is not in cross reaction with the human normal urothelium tissue and other non-urothelial carcinoma cells; according to mass spectrometric detection, the identified antigen is TNFRSF25. The invention also provides an in-vitro diagnosis kit comprising the monoclonal antibody DTUC1 and a method for detecting the content of tumor markers in urine by use of the monoclonal antibody DTUC1.

A medicament for treating cystitis and a method of treatment are provided. An agent to repair the damaged glycosaminoglycan (“GAG”) layers lining the urothelium, noted in cystitis, such as pentosan polysulfate, hyaluronic acid, chondroitin, etc., is provided in a liposomal carrier. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament.

The invention relates to methods for locally delivering a chemotherapeutic agent to an upper tract urothelial carcinoma (UTUC). The methods involve placing a balloon catheter that has a working channel and a balloon into the ureter / renal pelvis via retrograde or antegrade ureteral access; inflating the catheter balloon to temporarily obstruct the ureter; infusing (instilling) a liposomal formulation that includes a chemotherapeutic agent into the working channel of the catheter; and allowing the infused liposomal formulation to dwell in the ureter and / or renal pelvis for a time sufficient to allow at least a portion of the liposomal formulation to adhere to the urothelial wall. In the methods of the invention, at least a portion of the infused chemotherapeutic-agent formulation adheres tothe urothelial wall while it is instilled and dwells in the ureter and / or renal pelvis. The disclosed methods can be performed as an adjuvant therapy to other methods of treating UTUC, such as ureteroscopic ablation or resection of the tumor.

The present invention provides a method of treating melanoma and other cancers in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an herbal extract of PHY906 or Scutellaria baicalensis, a fraction thereof, or any active chemical present in the herbal extract or fraction thereof, and one or more immune checkpoint inhibitors. In certain embodiments, the method further comprises administering at least one herbal extract, a fraction thereof, or any active chemical present in the herbal extract or fraction thereof, of at least one herb selected from the group consisting of Glycyrrhiza uralensis, Paeonia lactiflora, and Ziziphus jujuba. The methods of the invention are useful for treating cancer such as melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer, and / or pancreatic cancer. In certain embodiments, administration of the herbal extracts of the invention counteract one or more gastrointestinal side effects of the immune checkpoint inhibitors and / or increase their therapeutic index against cancer.

A method for diagnosing, or differentially diagnosing, interstitial cystitis (IC) involves detecting or measuring increased expression of a biomarker Endothelin 1 (ET-1) in a biological sample from a mammalian subject, particularly in the urine or urothelial tissue. An increased level of expression of ET-1 above the level of expression in the same sample of a healthy mammalian subject is an indication of a diagnosis of IC. Such diagnosis may further involve identify other clinical symptoms of IC. Additionally the method may use additional biomarkers, such as Hb-EFG, EGF, APF, IL-8, IL-6, and cGMP. Assay methods and diagnostic reagents and kits for such diagnosis are provided. Methods and compositions for treating IC by reducing the action, production or synthesis of ET-1 in the urine or urothelium and / or inhibiting its binding to its ETA and / or ETB receptors are also provided.

A method for maintaining and / or enhancing the efficacy of a pharmaceutically active agent in a sustained-release treatment of a bladder disorder is disclosed. In preferred embodiments, the pharmaceutically active agent is botulinum toxin. The method comprises obtaining a biocompatible mucoadhesive thermoreversible hydrogel; and incorporating said pharmaceutically active agent for treatment of a bladder disorder into said biocompatible mucoadhesive thermoreversible hydrogel. The use of a biocompatible mucoadhesive thermoreversible hydrogel comprising a pharmaceutically active agent such as botulinum toxin in the treatment of bladder disorders, and a method for treating bladder disorders by the use of such a composition that does not require injection of the pharmaceutically active agent into the bladder wall, are also disclosed.

The invention discloses a traditional Chinese medicinal flushing liquid for a urinary system. The flushing liquid consists of the cooking extracts of coptis chinensis and scutellaria baicalensis, wherein the mass ratio of the coptis chinensis to the scutellaria baicalensis is 1 to 1; the cooking extracts of the coptis chinensis and the scutellaria baicalensis are extracted by the following processes: grinding the coptis chinensis and the scutellaria baicalensis into fine powder, respectively soaking the coptis chinensis and the scutellaria baicalensis fine powder in distilled water for 0.8-2hr, and boiling twice with slow fire, wherein each time lasts for 20-40min; decompressing and filtering, combining filtrates of two times, decompressing, concentrating and recovering a solvent, wherein medicinal liquid concentration is 1g of crude drugs in per milliliter; and regulating pH value to 6-7 and regulating osmotic pressure by virtue of sodium chloride and sodium hydrogen carbonate. The traditional Chinese medicinal flushing liquid can be used for inhibiting the growth of bacteria, relieving irritative symptoms, promoting mucosa repair and improving local immune state; by regulating the pH value and the osmotic pressure by virtue of the sodium chloride and the sodium hydrogen carbonate, the traditional Chinese medicinal flushing liquid is more adaptive to the physiological characteristics of urothelium regional anatomy; the flushing liquid is suitable for various patients of indwelling catheter and has a significant treating effect on related infections of catheter. The flushing liquid disclosed by the invention is low in production cost and capable of remarkably reducing the flushing cost in urinary operations.

The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety. The present invention provides pharmaceutical compositions for the treatment of cancer comprising an antibody that binds to 67LR in an amount effective to reduce cancer stem cells and / or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.

A method for diagnosing, or differentially diagnosing, interstitial cystitis (IC) involves detecting or measuring increased expression of a biomarker Endothelin 1 (ET-1) in a biological sample from a mammalian subject, particularly in the urine or urothelial tissue. An increased level of expression of ET-1 above the level of expression in the same sample of a healthy mammalian subject is an indication of a diagnosis of IC. Such diagnosis may further involve identify other clinical symptoms of IC. Additionally the method may use additional biomarkers, such as Hb-EFG, EGF, APF, IL-8, IL-6, and cGMP. Assay methods and diagnostic reagents and kits for such diagnosis are provided. Methods and compositions for treating IC by reducing the action, production or synthesis of ET-1 in the urine or urothelium and / or inhibiting its binding to its ETA and / or ETB receptors are also provided.

The invention relates to the field of biotechnology and medical diagnosis, in particular to application of chromosome instable regions to preparing an agent or kit for the diagnosis of urothelium carcinoma. There are ten chromosome instable regions 3p, 3q, 5p, 7p, 7q, 8q, 9p, 9q, 17p and 17q. Samples of clinically confirmed urothelium carcinoma patients, healthy people and non-urothelium-carcinomapatients are collected, the specific chromosome instability distribution characteristics of the urothelium carcinoma are expounded by comparing chromosome abnormity conditions of the tumor patients and the contrast through whole-genome sequencing, the ten common chromosome instable regions of the urothelium carcinoma patients are disclosed, and the total carrying rate is up to 93.4%, which has great significance in the clinical diagnosis, treatment, monitoring, prognosis and evaluation of the urothelium carcinoma and provides the scientific basis for conducting early diagnosis next and formulating an individualized treatment scheme.

TERT promoter mutations occur in both papillary and flat lesion bladder cancers, are the most frequent genetic alterations identified to date in noninvasive precursor lesions of the bladder, are detectable in urine, and appear to be strongly associated with bladder cancer recurrence. The TERT promoter mutations are useful urinary biomarker for both the early detection and monitoring of bladder neoplasia.

The invention discloses gynostemma pentaphylla rinsing liquid with an inhibitory effect on urothelium malignant potential proliferation and a preparation method and application thereof. The rinsing liquid contains rich flavone and saponin components; the preparation method of the rinsing liquid comprises the steps that the reflux extraction of the coarse powder of the dried gynostemma pentaphyllais conducted through ethanol solution, and the extractum extracted by ethanol is obtained by conducting vacuum concentration; the extractum is absorbed by using macroporous resin after high-temperature and high-pressure processing is conducted on the extractum, and the extractum is desorbed to obtain gynostemma pentaphylla extracts; gynostemma pentaphylla powder extracts are obtained after freezing and drying are conducted, and the gynostemma pentaphylla rinsing liquid is obtained by conducting proportioning by using normal saline. Pharmacodynamic experiments reveal that the gynostemma pentaphylla rinsing liquid has a more significant effect on inhibiting the urothelium malignant potential proliferation. The gynostemma pentaphylla rinsing liquid has the advantages of being simple in preparation, safe in components, free from toxins and side effects, stable in active ingredients and simple in rinsing manner.

The invention relates to methods for locally delivering a chemotherapeutic agent to an upper tract urothelial carcinoma (UTUC). The methods involve placing a balloon catheter that has a working channel and a balloon into the ureter / renal pelvis via retrograde or antegrade ureteral access; inflating the catheter balloon to temporarily obstruct the ureter; infusing (instilling) a liposomal formulation that includes a chemotherapeutic agent into the working channel of the catheter; and allowing the infused liposomal formulation to dwell in the ureter and / or renal pelvis for a time sufficient to allow at least a portion of the liposomal formulation to adhere to the urothelial wall. In the methods of the invention, at least a portion of the infused chemotherapeutic-agent formulation adheres to the urothelial wall while it is instilled and dwells in the ureter and / or renal pelvis. The disclosed methods can be performed as an adjuvant therapy to other methods of treating UTUC, such as ureteroscopic ablation or resection of the tumor.

Cell binding peptides are provided for binding to cells including urothelial and thyroid follicular cells. The peptides are useful for detection and diagnosis of cancer including bladder and thyroid cancer. A device and method for using the device for capturing cells is provided, the device includes a support having attached cell binding peptide. The support can be a slide and the device can be used for detection and diagnosis of cancer including bladder and thyroid cancer. A kit is provided with instructions for capturing cells and a support with attached cell binding peptide for detection and diagnosis of bladder and thyroid cancer.

The invention discloses a urine detection kit for diagnosing urothelium carcinoma. The urine detection kit comprises capture reagent, detection reagent, coating buffer solution, scrubbing solution, color-producing reagent and termination reagent. The capture reagent is anti-Neu5Gc primary antibody, and the detection agent is anti-Neu5Gc second antibody. The kit disclosed by the invention is high in sensitivity and has the advantage of the urine exfoliocytology, the problem that the urine exfoliocytology is low in sensitivity is overcome, and the kit can be used for the early screening of the urothelium carcinoma.

Provided herein are urine progenitor cells and methods for producing a culture of urine progenitor cells from a urine sample. The cells may be selected based upon the use of a selective cell medium, based upon morphology, and / or by selecting cell-specific markers. Also provided is an isolated urine progenitor cell that is c-kit positive and can differentiate into urothelium, smooth muscle, endothelium or interstitial cells. Methods of use of urine progenitor cells are provided, wherein cell are seeded onto a tissue scaffold are provided. Methods of treating a subject in need thereof are also provided, including providing a bladder tissue substrate that includes differentiated UPCs and transplanting the substrate into the patient. Finally, kits are provided that include a container suitable for the transport of a urine sample; media; one or more antibiotics; a package for holding said container, media, and antibiotics; and optionally, instructions for use.

The invention provides a new human urothelial carcinoma tumor marker-human tumor necrosis factor receptor superfamily TNFRSF25 and a hybridoma cell generating a monoclonal antibody resisting the tumor marker and a monoclonal antibody DTUC1 secreted thereby, wherein the monoclonal antibody DTUC1 is secreted by the hybridoma with collection number CGMCC No.8118. The monoclonal antibody DTUC1 is in positive reaction with the human urothelial carcinoma tissue and urothelial carcinoma cell lines such as 5637, UMUC3, SW780, J82, T24 and RT4, and is not in cross reaction with the human normal urothelium tissue and other non-urothelial carcinoma cells; according to mass spectrometric detection, the identified antigen is TNFRSF25. The invention also provides an in-vitro diagnosis kit comprising the monoclonal antibody DTUC1 and a method for detecting the content of tumor markers in urine by use of the monoclonal antibody DTUC1.

The invention relates to a medicinal preparation for treating the bladder cancer and an application thereof. The medicinal preparation is prepared from rhizoma smilacis glabrae, pseudo-ginseng, radix sophorae flavescentis, cordyceps sinensis, cinnamon, scorpions, dried bodies of ground beetles, curcuma zedoary, pangolin, sculellaria barbata, ginseng, oldenlandia diffusa, fructus lycii, fructus forsythiae, lithospermum, radix angelica sinensis, Chinese dates, scutellaria baicalensis, lophatherum gracile, lucid ganoderma, honeysuckle, dark plums, ginger and liquorice roots. The medicinal preparation has a remarkable treatment effect on the bladder cancer, and is free of toxic and side effects, relapse is not prone to happen, and has a better treatment effect especially on early-to-mid urothelium bladder cancers. A preparation method of the preparation is simple, effective and good in stability, the regeneration capacity of immune cells can be effectively stimulated, the immunity of a patient can be improved, and the medicinal preparation is worthy of being applied and popularized clinically.

The invention discloses a porous bladder acellular matrix retaining bioactive factors and a preparation method thereof. A bladder of a pig, a rabbit, a dog or cattle is handled by digestive juice, hypotonic buffer solution, hypertonic buffer solution with surfactants, buffer solution with nuclease, and deionized water. An abacterial bladder acellular matrix is obtained by cooling, freezing out and sterilizing. The bladder acellular matrix is not provided with cells, an urinary tract epithelial layer, a submucous layer or a blood circulatory system, thus having good biocompatibility and appropriate ultrastructural structure. Bioactive factors are retained, including cell adhesive factors, growth factors and chemokines. Therefore, the bladder acellular matrix is an ideal scaffold material for a bladder in tissue engineering.

The invention discloses a specific primer and probe combination for qPCR (quantitative polymerase chain reaction) quantitative detection of copy number of target genes of urothelial carcinoma and application of the specific primer and probe combination. The method comprises the following steps: detecting amplification Ct values of four genes, namely CDKN2A, NUMA1, FOSL2 and BECN1, related to urothelial carcinoma in urine precipitation DNA (Deoxyribose Nucleic Acid) by utilizing a multiple real-time fluorescent quantitative PCR (Polymerase Chain Reaction) method, and respectively calculating copy numbers of the four genes by taking two genes, namely CFTR1 and POP1 as internal references and adopting a 2-delta delta Ct method (Livak method). And a prediction model for auxiliary diagnosis of the urothelium carcinoma is established by using the urine sediment DNA of 50 urothelium carcinoma patients and 30 normal persons.

The invention relates to aminopyrimidinopyrazole / pyrrole derivatives as well as a preparation method and application thereof, belonging to the field of medicines. The invention provides compounds derivatives as shown in a formula I which is described in the specification and optical isomers thereof, and further provides pharmaceutically acceptable salts of the compounds or the optical isomers thereof. Biological experiments prove that the compounds can remarkably inhibit proliferation of various cancer cells such as breast cancer, lung cancer, colorectal cancer, gastric cancer, bile duct cancer and urothelium carcinoma, have a broad-spectrum anticancer effect, also show an inhibiting effect on proliferation of fibroblasts and hepatic stellate cells, can inhibit growth of tumors in vivo, have wide application prospects and provide a new choice for the development of anti-tumor and anti-fibrosis medicines.

The present invention concerns the use of protein biomarkers for use in facilitating in the prognosis and / or treatment regime of bladder cancer. In particular, the invention relates to the use of shed protein fragments, such as fragments of Epithelial cell adhesion molecule (EpCAM) and / or epidermal growth factor receptor (EGFR) detected in a sample of urine, as biomarkers for use in facilitating the prognosis and / or treatment regime of urothelial bladder cancer.